Sign in

NCT05007847Completed

Improving AF Detection in Cryptogenic Stroke

A Non-invasive, Prolonged Surveillance Strategy Using Apple Watch for Atrial Fibrillation Detection in Cryptogenic Stroke

Source: ClinicalTrials.gov · Last updated 25 Mar 2025

Brief summary (registry, in English)

No cause for stroke is found in up to 30% of cases despite extensive investigations. These are called cryptogenic strokes (CS). 1 in 4 stroke survivors will suffer another in 5 years and this is a leading cause of fear and anxiety. A common reason for CS is an undetected heart rhythm disorder called atrial fibrillation (AF). AF occurs intermittently, so it may not be detected during the mandated 24-96 hours of rhythm monitoring that is performed as part of the standard post-stroke investigation strategy. A randomised controlled study in 2014 showed that whereas this standard monitoring strategy picks up AF in 2% of CS patients, longer-term, continuous monitoring for 12 months can pick up AF in 13% of patients. This suggests the standard strategy may miss AF in a proportion of CS patients and thus also the opportunity to mitigate against further strokes with anticoagulation therapy. Prolonged monitoring has traditionally required a minimally-invasive surgical procedure to implant a recording device under the skin at a specialist centre. A specifically trained team is also required to interpret the large number of recordings this strategy yields. The Apple Watch (AW) is a wristwatch able to monitor a wearer's heart rate and rhythm regularity and facilitates real- time, single-lead ECG recordings. This over-the-counter, non-invasive device has demonstrated feasibility and has a Certification (CE) Mark for detecting AF. It may offer a potential non-invasive alternative long-term rhythm surveillance strategy to diagnose AF in these patients. The investigators propose a study in which CS patients will be randomised in a 1:1 ratio to receive additional AW monitoring on top of standard care versus standard care alone. The investigators shall then explore the incidence of AF in the two groups at 1 year and how it impacts clinical outcomes too.

Status (registry)
Completed
Study type
Interventional
Enrollment
27 (actual)
First submitted
14 Jul 2021
Start date
4 Feb 2022
Primary completion date
28 Feb 2025
Lead sponsor
Barts & The London NHS Trust
NCT number
NCT05007847

What you commit to

  • Study type: Interventional
  • Participants enrolled: 27
  • From 4 Feb 2022 to the primary completion date, 28 Feb 2025
  • 4 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Any episode of myocardial infarction, coronary intervention or coronary artery bypass grafting \<1 month prior to the stroke event
  • Previous left atrial (LA) ablation or LA surgery

Other illness

  • Documented history of AF or atrial flutter.
  • Expected to undergo heart surgery in the 1 year following the stroke event.
  • Patient has a cardiac implantable electronic device in-situ already or is expected to undergo implantation in the 1 year following the stroke event (excluding implantable loop recorder for the investigation of the CS).

Other

  • Any other indication for oral anti-coagulation.
  • Life expectancy less than 1 year

Who the study is looking for

  • Recent stroke or TIA event (\<90 days) that is supported by consistency between symptoms and findings on brain magnetic resonance imaging (MRI) or computed tomography (CT). Patients with TIA will be enrolled only if symptoms at presentation were speech problems, limb weakness, or hemianopsia. Diagnosis shall be made by a Consultant Stroke physician.
  • Stroke classified as cryptogenic following extensive investigations to rule out a cause as per local protocol, but to include at least:
    • Trans-thoracic echocardiogram
    • A period of at least 24-hour rhythm monitoring with no evidence of AF.
    • MRI or CT-angiography of the brain
  • Sufficient mobility and dexterity to perform an ECG recording on the AW by touching the dial on the watch when worn with the contralateral hand for 30 seconds.
  • Access to a smartphone with Apple-operating system (OS) within their household for syncing with their watch.
  • Participants must be able and willing to provide written informed consent to participate in the study.

Age in the registry: 30 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (4)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
St Bartholomew's Hospital
Coordinator of this site? Confirm its status
City of LondonUnited KingdomUnknown status
The National Hospital for Neurology and Neurosurgery
Coordinator of this site? Confirm its status
LondonUnited KingdomUnknown status
Whipps Cross University Hospital
Coordinator of this site? Confirm its status
LondonUnited KingdomUnknown status
Royal London Hospital
Coordinator of this site? Confirm its status
LondonUnited KingdomUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.